Phenylbutyrate inhibits the invasive properties of prostate and breast cancer cell lines in the sea urchin embryo basement membrane invasion assay

International Journal of Cancer

Volumn 101, Issue 5, 2002, Pages 496-499

  Dyer, Erica S ^a   Paulsen, Michelle T ^a   Markwart, Sonja M ^a   Goh, Meidee ^a   Livant, Donna L ^a   Ljungman, Mats ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Basement membrane; Butyrate; Histone deacetylase inhibitor; Invasion; Invasion assay; Sea urchin embryo

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; BASEMENT MEMBRANE; BIOASSAY; BREAST CARCINOMA; CANCER CELL CULTURE; CELL INVASION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; EMBRYO; HUMAN; INVASIVE CARCINOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; SEA URCHIN;

ANIMALS; BIOLOGICAL ASSAY; BREAST NEOPLASMS; CELL DIVISION; EMBRYO, NONMAMMALIAN; FEMALE; HUMANS; MALE; NEOPLASM INVASIVENESS; PHENYLBUTYRATES; PROSTATIC NEOPLASMS; SEA URCHINS; TUMOR CELLS, CULTURED;

EID: 0037057516     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10609     Document Type: Article

References (27)

1. Modifying histones to tame cancer: Clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors
2. Histone deacetylases and cancer: Causes and therapies
3. Effect of butyrate on gene expression
4. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells
5. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate
6. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate
7. Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo
8. Enhancement of radiation injury in human colon tumor cells by the maturational agent sodium butyrate (NaB)
9. Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrate
10. Phenylbutyrate attenuates the expression of Bcl-X-L, DNA-PK, caveolin-1, and VEGF in prostate cancer cells
11. Butyrate attenuates BCLXL expression in human fibroblasts and acts in synergy with ionizing radiation to induce apoptosis
12. Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents
13. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis
14. Role of urokinase receptor and caveolin in regulation of integrin signaling
15. Metastasis-related genes in prostate cancer: The role of caveolin-1
16. Elevated expression of caveolin is associated with prostate and breast cancer
17. Metastasis-related genes in prostate cancer
18. Inhibitory effects of phenylbutyrate on the proliferation, morphology, migration and invasiveness of malignant glioma cells
19. Inhibitory effect of 1-O (2 methoxy) hexadecyl glycerol and phenylbutyrate on the malignant properties of human prostate cancer cells
20. Invasion of selectively permeable sea urchin embryo basement membranes by metastatic tumor cells, but not by their normal counterparts
21. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma
22. Migratory and invasive behavior of pigment cells in normal and animalized sea urchin embryos
23. Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors
24. Genes related to growth and invasiveness are repressed by sodium butyrate in ovarian carcinoma cells
25. Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype
26. Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation
27. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies